# HCPLive

> HCPLive - Healthcare Publication

- Base URL: https://www.hcplive.com
- Generated: 2026-10-18T22:27:48.984Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.hcplive.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.hcplive.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.hcplive.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.hcplive.com/robots.txt](https://www.hcplive.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [10 Year Plan Series](https://www.hcplive.com/10-year-plan-series)
- [Advanced Practitioners Corner](https://www.hcplive.com/advanced-practitioners-corner)
- [Clinical](https://www.hcplive.com/clinical)
- [Clinical Trial Insights](https://www.hcplive.com/clinical-trial-insights)
- [Conference](https://www.hcplive.com/conference)
- [Explore the Endogenous Opioid System And its Potential Impact on MDD](https://www.hcplive.com/alkermes)
- [Insights](https://www.hcplive.com/insights)
- [Insights](https://www.hcplive.com/insights)
- [Journals](https://www.hcplive.com/journals)
- [Medcast Videos](https://www.hcplive.com/medcast-videos)
- [NO ADS](https://www.hcplive.com/noads)
- [News](https://www.hcplive.com/news)
- [Peer Exchange](https://www.hcplive.com/peer-exchange)
- [Peers Perspectives](https://www.hcplive.com/peers-perspectives)
- [Physician's Money Digest](https://www.hcplive.com/physicians-money-digest)
- [Plastic surgery](https://www.hcplive.com/plastic-surgery)
- [Podcasts](https://www.hcplive.com/podcasts)
- [Post Conference Perspectives](https://www.hcplive.com/post-conference-perspectives)
- [Practice Brief](https://www.hcplive.com/practice-brief)
- [Press Release](https://www.hcplive.com/press-release)
- [Publications](https://www.hcplive.com/journals)
- [Q1 Awareness Highlights](https://www.hcplive.com/q1-awareness-highlights)
- [Qazi Corner](https://www.hcplive.com/qazi-corner)
- [Quizzes](https://www.hcplive.com/quizzes)
- [Rosacea](https://www.hcplive.com/rosacea)
- [Shows](https://www.hcplive.com/shows)
- [Special Reports](https://www.hcplive.com/news-network)
- [Sponsored](https://www.hcplive.com/sponsored)
- [Strategic Alliance Partnership](https://www.hcplive.com/sap-partner)
- [The Respiratory Report](https://www.hcplive.com/respiratory-report)
- [This Year In Medicine](https://www.hcplive.com/this-year-in-medicine)
- [Venous Thromboembolism](https://www.hcplive.com/vte)
- [Video Series](https://www.hcplive.com/video-series)
- [Videos](https://www.hcplive.com/videos)

## Featured Content

- [Can Nemolizumab Help Children Under 12 with Moderate-to-Severe Eczema?](https://www.hcplive.com/view/can-nemolizumab-help-children-under-12-moderate-severe-eczema-): Children aged 2 - 11 with atopic dermatitis saw early, lasting itch and sleep gains with nemolizumab through 1 year in phase 2 data shared at PeDRA 20...
- [Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD](https://www.hcplive.com/view/mepolizumab-reduces-systemic-corticosteroid-exposure-eosinophilic-copd): In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.
- [Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations ](https://www.hcplive.com/view/chronic-proton-pump-inhibitor-linked-more-asthma-exacerbations): Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched coh...
- [I-124 Evuzamitide PET/CT Highly Sensitive, Specific in Amyloid Detection](https://www.hcplive.com/view/i-124-evuzamitide-pet-ct-highly-sensitive-specific-in-amyloid-detection): Mathew Maurer, MD, discusses the results of the phase 3 REVEAL study, which highlighted this novel scanning technology’s capacity for identifying amyl...
- [Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD](https://www.hcplive.com/view/tozorakimab-mucus-plugging-copd-washko): George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.
- [Biologic Access in Asthma and COPD: Clinical Forum Perspectives](https://www.hcplive.com/view/biologic-access-asthma-copd-clinical-forum-perspectives): Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.
- [Treatable Traits in Asthma and COPD: Clinical Forum Perspectives](https://www.hcplive.com/view/treatable-traits-asthma-copd-clinical-forum-perspectives): Participants said payer criteria and patient goals often outweigh mechanism when choosing biologics, and that shared decision-making is harder in COPD...
- [Maralixibat Reduces Cholestatic Pruritus in Phase 3 EXPAND, With Jennifer Vittorio, MD](https://www.hcplive.com/view/maralixibat-reduces-cholestatic-pruritus-in-phase-3-expand-with-jennifer-vittorio-md): Jennifer Vittorio, MD, discusses EXPAND pruritus and serum bile acid results, the ItchRO(Obs) endpoint, and implications for biliary atresia.
- [Alpha-Gal Syndrome Clues Clinicians Miss, With Chirag Patel, MD](https://www.hcplive.com/view/alpha-gal-syndrome-clues-clinicians-miss-patel): Chirag Patel, MD, explains why reaction timing, isolated abdominal pain, and careful test interpretation are central to recognizing alpha-gal syndrome...
- [Dyspnea Worsens in 1 in 3 Patients Following Discharge from HF Hospitalization](https://www.hcplive.com/view/dyspnea-worsens-in-1-in-3-patients-following-discharge-from-hf-hospitalization): Quin Denfeld, PhD, discusses her findings from the BIOMES-HF study, indicating worsening symptoms in patients with HF over time.

## Feeds and Indexes

- [RSS Feed](https://www.hcplive.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.hcplive.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.hcplive.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.hcplive.com/authors): Browse all contributors and their published work